Steatohepatitis: Difference between revisions
imported>Robert Badgett (→Increasing insulin sensitivity: Added metformin stuff) |
imported>Robert Badgett (→Increasing insulin sensitivity: Added DOIs) |
||
Line 31: | Line 31: | ||
===Increasing insulin sensitivity=== | ===Increasing insulin sensitivity=== | ||
[[Metformin]], a [[biguanide]] that increases insulin sensitivity and has additional effects, may help according to preliminary studies.<ref name="pmid11567710">{{cite journal| author=Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N| title=Metformin in non-alcoholic steatohepatitis. | journal=Lancet | year= 2001 | volume= 358 | issue= 9285 | pages= 893-4 | pmid=11567710 | [[Metformin]], a [[biguanide]] that increases insulin sensitivity and has additional effects, may help according to preliminary studies.<ref name="pmid11567710">{{cite journal| author=Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N| title=Metformin in non-alcoholic steatohepatitis. | journal=Lancet | year= 2001 | volume= 358 | issue= 9285 | pages= 893-4 | pmid=11567710 |doi=10.1016/S0140-6736(01)06042-1 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11567710 }} </ref><ref name="pmid15225167">{{cite journal| author=Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP| title=Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. | journal=Aliment Pharmacol Ther | year= 2004 | volume= 20 | issue= 1 | pages= 23-8 | pmid=15225167 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11567710 }} </ref><ref name="pmid15225167">{{cite journal| author=Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP| title=Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. | journal=Aliment Pharmacol Ther | year= 2004 | volume= 20 | issue= 1 | pages= 23-8 | pmid=15225167 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15225167 | doi=10.1111/j.1365-2036.2004.02025.x }} </ref><ref name="pmid14987322">{{cite journal| author=Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al.| title=Metformin in the treatment of patients with non-alcoholic steatohepatitis. | journal=Aliment Pharmacol Ther | year= 2004 | volume= 19 | issue= 5 | pages= 537-44 | pmid=14987322 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15225167 | doi=10.1111/j.1365-2036.2004.02025.x }} </ref><ref name="pmid14987322">{{cite journal| author=Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al.| title=Metformin in the treatment of patients with non-alcoholic steatohepatitis. | journal=Aliment Pharmacol Ther | year= 2004 | volume= 19 | issue= 5 | pages= 537-44 | pmid=14987322 |doi=10.1111/j.1365-2036.2004.01888.x | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=14987322 }} </ref><ref name="pmid15842582">{{cite journal| author=Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al.| title=A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. | journal=Am J Gastroenterol | year= 2005 | volume= 100 | issue= 5 | pages= 1082-90 | pmid=15842582 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=14987322 }} </ref><ref name="pmid15842582">{{cite journal| author=Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al.| title=A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. | journal=Am J Gastroenterol | year= 2005 | volume= 100 | issue= 5 | pages= 1082-90 | pmid=15842582 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15842582 | doi=10.1111/j.1572-0241.2005.41583.x }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15842582 | doi=10.1111/j.1572-0241.2005.41583.x }} </ref> | ||
[[Thiazolidinedione]] derivatives, normally used for treating [[diabetes mellitus type 2]] by increasing sensitivity to [[insulin]], have been studied for the treatment of nonalcoholic steatohepatitis. | [[Thiazolidinedione]] derivatives, normally used for treating [[diabetes mellitus type 2]] by increasing sensitivity to [[insulin]], have been studied for the treatment of nonalcoholic steatohepatitis. |
Revision as of 10:03, 6 May 2010
In medicine, steatohepatitis is a liver disease characterized by fatty liver and lobular hepatitis.[1]
Hepatitis, inflammation of the liver, can be detected by liver biopsy, or can be suggested by elevated blood levels of tumor necrosis factor - alpha (TNF-alpha) and transforming growth factor beta (TGF-beta).[2]
Classification
Alcoholic steatohepatitis
Nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) is associated with obesity, diabetes mellitus, or hyperlipidemia.[1] NASH may be caused by the single-nucleotide polymorphisms rs2854116 (c.455T>C) and rs2854117 (c.482C>T) of apolipoprotein C-III which are also associated with insulin resistance and hypertriglyceridemia.[3]
Treatment
Weight loss may help.[4]
Antioxidants
Vitamin E, an antioxidant, may improve liver histology in a randomized controlled trial of 247 patients who did not have diabetes.[5]
In 2005, a meta-analysis concluded that Vitamin E supplementation may actually be harmful when used for the prevention of vascular disease.[6]
Cholesterol reduction
Simvastatin did not help in a pilot study.[7]
Increasing insulin sensitivity
Metformin, a biguanide that increases insulin sensitivity and has additional effects, may help according to preliminary studies.[8][9][10][11]
Thiazolidinedione derivatives, normally used for treating diabetes mellitus type 2 by increasing sensitivity to insulin, have been studied for the treatment of nonalcoholic steatohepatitis.
Pioglitazone did not improve liver histology in a randomized controlled trial of 247 patients who did not have diabetes.[5]
Previously, pioglitazone improved nonalcoholic steatohepatitis in patients with impaired glucose tolerance or diabetes mellitus type 2 according to a preliminary randomized controlled trial of 55 patients.[2] Also, rosiglitazone improved histology and liver transaminases in a trial 63 patients that excluded patients taking insulin (30% had diabetes and were taking other drugs)[12], with longer treatment of 44 patients[13].
Surgery
While bariatric surgery would seem effective, it has not been studied.[14]
References
- ↑ 1.0 1.1 Sheth SG, Gordon FD, Chopra S (1997). "Nonalcoholic steatohepatitis.". Ann Intern Med 126 (2): 137-45. PMID 9005748.
- ↑ 2.0 2.1 Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. (2006). "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.". N Engl J Med 355 (22): 2297-307. DOI:10.1056/NEJMoa060326. PMID 17135584. Research Blogging.
Cite error: Invalid
<ref>
tag; name "pmid17135584" defined multiple times with different content - ↑ Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM et al. (2010). "Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.". N Engl J Med 362 (12): 1082-9. DOI:10.1056/NEJMoa0907295. PMID 20335584. Research Blogging.
- ↑ Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. (2010). "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.". Hepatology 51 (1): 121-9. DOI:10.1002/hep.23276. PMID 19827166. PMC PMC2799538. Research Blogging.
- ↑ 5.0 5.1 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. (2010). "Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.". N Engl J Med. DOI:10.1056/NEJMoa0907929. PMID 20427778. Research Blogging.
Cite error: Invalid
<ref>
tag; name "pmid20427778" defined multiple times with different content - ↑ Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (January 2005). "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality". Ann. Intern. Med. 142 (1): 37–46. PMID 15537682. [e]
- ↑ Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009 Nov-Dec). "A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.". J Clin Gastroenterol 43 (10): 990-4. DOI:10.1097/MCG.0b013e31819c392e. PMID 19448566. Research Blogging.
- ↑ Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001). "Metformin in non-alcoholic steatohepatitis.". Lancet 358 (9285): 893-4. DOI:10.1016/S0140-6736(01)06042-1. PMID 11567710. Research Blogging.
- ↑ Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP (2004). "Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.". Aliment Pharmacol Ther 20 (1): 23-8. DOI:10.1111/j.1365-2036.2004.02025.x. PMID 15225167. Research Blogging.
- ↑ Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al. (2004). "Metformin in the treatment of patients with non-alcoholic steatohepatitis.". Aliment Pharmacol Ther 19 (5): 537-44. DOI:10.1111/j.1365-2036.2004.01888.x. PMID 14987322. Research Blogging.
- ↑ Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. (2005). "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.". Am J Gastroenterol 100 (5): 1082-90. DOI:10.1111/j.1572-0241.2005.41583.x. PMID 15842582. Research Blogging.
- ↑ Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L et al. (2008). "Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.". Gastroenterology 135 (1): 100-10. DOI:10.1053/j.gastro.2008.03.078. PMID 18503774. Research Blogging.
- ↑ Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G et al. (2010). "Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.". Hepatology 51 (2): 445-53. DOI:10.1002/hep.23270. PMID 19877169. Research Blogging.
- ↑ Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M (2010). "Bariatric surgery for non-alcoholic steatohepatitis in obese patients.". Cochrane Database Syst Rev (1): CD007340. DOI:10.1002/14651858.CD007340.pub2. PMID 20091629. Research Blogging.